- cafead   Oct 30, 2021 at 10:52: PM
via AbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving the way for regulatory filings.
article source
article source